Harvest Fund Management Co. Ltd Raises Position in Masimo Co. (NASDAQ:MASI)

Harvest Fund Management Co. Ltd increased its holdings in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 339.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,891 shares of the medical equipment provider's stock after buying an additional 3,005 shares during the quarter. Harvest Fund Management Co. Ltd's holdings in Masimo were worth $656,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in MASI. Jones Financial Companies Lllp purchased a new stake in shares of Masimo during the fourth quarter worth about $27,000. UMB Bank n.a. boosted its stake in Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock worth $32,000 after purchasing an additional 123 shares in the last quarter. Trust Co. of Vermont purchased a new stake in Masimo during the 4th quarter worth approximately $33,000. Blue Trust Inc. increased its stake in Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 71 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after buying an additional 64 shares during the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

Masimo Stock Performance

Masimo stock traded up $2.09 during midday trading on Tuesday, hitting $169.70. 476,981 shares of the company were exchanged, compared to its average volume of 625,501. The business has a fifty day simple moving average of $175.03 and a two-hundred day simple moving average of $160.20. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The firm has a market capitalization of $9.16 billion, a PE ratio of 117.03 and a beta of 1.04. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $194.88.

Remove Ads

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $600.70 million for the quarter, compared to analysts' expectations of $593.35 million. On average, sell-side analysts forecast that Masimo Co. will post 4.1 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on MASI. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a report on Wednesday, February 26th. Wells Fargo & Company boosted their price target on Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Raymond James lifted their target price on Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a report on Friday, December 27th. Finally, Piper Sandler increased their price target on shares of Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Masimo has a consensus rating of "Moderate Buy" and an average target price of $194.80.

Insiders Place Their Bets

In other news, Director Craig B. Reynolds sold 2,053 shares of the business's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now directly owns 16,581 shares in the company, valued at $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Bilal Muhsin sold 30,000 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the transaction, the chief operating officer now owns 24,172 shares in the company, valued at $4,048,568.28. This trade represents a 55.38 % decrease in their position. The disclosure for this sale can be found here. Insiders own 9.70% of the company's stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.